CECAD Microsite

Overview

Cancer is the leading cause of death worldwide and its numbers are projected to rise further, resulting in an estimated 12 million deaths in 2030. Current standard therapies, such as chemo- and radiation therapy have yielded significant benefit in a few cancer entities, but long-term survival gains are uncommon, especially for advanced disease. Thus, these treatments are insufficient by themselves to combat the escalating trend in cancer mortality. Targeted therapies that build on tumor-specific vulnerabilities have shown great promise over recent years. However, we still lack a sound understanding of these tumor-specific vulnerabilities.

We use a three-pronged experimental approach to identify, validate and clinically exploit tumor-specific molecular liabilities. We use a large collection of genomically well-annotated human and murine cancer cell lines in conjunction with a large-scale screening platform to identify compounds, or compound combinations, that induce genotype-specific cytotoxicity. Once promising hits have been identified, we validate these in vitro observations on our in vivo platform, which contains genetically engineered mouse models mimicking a wide range of human malignancies, ranging from chronic lymphocytic leukemia, small cell and non-small cell lung cancer, pancreatic ductal adenocarcinoma, sarcoma and breast cancer. Lastly, we actively cooperate with our clinical partners, as well as the pharmaceutical industry to translate our findings into clinical testing and application.